Thoracic Medical Oncologist @MassGenBrigham @MGHThoracicOnc @HarvardMed | #TargetedTherapies #ADCs #EarlyDrugDevelopment #LungCancer
Joined June 2019
- Tweets500
- Following905
- Followers1.4K
- Likes2.6K
Sarah Waliany, MD, MS retweeted
Presented at #ESMO26:
In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: nej.md/4iveIgW
@myESMO
ALT A graph from the Original Article "Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer." The trial name, DeLLphi-305, is in parentheses after the title. The graph shows the overall survival (intention-to-treat population). The trial results are being presented at the European Society For Medical Oncology 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.
Sarah Waliany, MD, MS retweeted
Pope Leo XIV has been diagnosed with lung adenocarcinoma.
While we had hoped for a different diagnosis, the fact that he was able to undergo a lobectomy is encouraging. Surgery is generally pursued when lung cancer appears localized and potentially curable.
Final pathology will help determine prognosis and whether additional treatment is needed.
Wishing the Holy Father a smooth and speedy recovery.
lombardi.georgetown.edu/lomb…
Sarah Waliany, MD, MS retweeted
Update on COPERNICUS study from @BalazsHalmosMD at #WCLC26 shows impact of supportive care strategies from COCOON with 1L subcutaneous amivantamab + lazertinib for EGFR mt NSCLC.
Compared to published MARIPOSA results, rate paronychia was 35% from 50%, rash 25% from 55%, VTE 3% from 23%, IRR 3% from 55%. Discontinuation of amivantamab in the first year due to AESI was < 1% (vs 9% in MARIPOSA).
Sarah Waliany, MD, MS retweeted
Early insights into resistance to HER2 TKIs in NSCLC emerged at #WCLC26. Zongertinib & sevabertinib now both approved as 1L+ treatment for advanced NSCLC with a HER2 TKD mt. While efficacy similar, these are distinct agents and we need to learn how to leverage those differences.
Sarah Waliany, MD, MS retweeted
Dr. @alexdrilon at #WCLC26 presents 1L cohort of ARROS-1 trial of zidesamtinib in pts with ROS1 NSCLC. What a waterfall plot. RR 94% with 15% CR. mPFS not reached, PFS at 6m was 96% and at 12m was 90%. Intracranial RR 100%. In 78 pts who did not have brain metastases at baseline, no CNS events occurred to date. These are fantastic outcomes.
Sarah Waliany, MD, MS retweeted
Landmark, practice changing study at #WCLC26. The phase III MAVERICK study shows no improvement in OS with PCI for SCLC, across limited and extensive stages, with worse cognitive failure free survival and increased toxicity in PCI arm.
The end of the PCI era.
Sarah Waliany, MD, MS retweeted
A wonderful #BCVS2026 @AHAScience @AHAMeetings w/ trainees & colleagues. Honored to talk about our project targeting ici myocarditis while sparing tumor @yinsun96. Proud of @.Hiranyasundar for winning a predoc poster award. Awesome to eat w good friends @AnjaKarlstaedt @SWaliany
Sarah Waliany, MD, MS retweeted
🌟This is history
⭐️The most awaited abstract
👏 Standing ovation at Hall B1
💊 Daraxonrasib becomes the new standard of care for patients with previously treated metastatic #pancreatic #cancer
#ASCO26
Sarah Waliany, MD, MS retweeted
ALK-positive NSCLC remains one of the most rapidly evolving spaces in thoracic oncology. 🫁
Interesting data from the multicenter retrospective study led by @SWaliany evaluating continuation of next-generation ALK TKIs alongside platinum/pemetrexed chemotherapy after progression.
The study suggested potential improvements in PFS/OS and reduced CNS progression, particularly in patients treated upfront with 2G/3G ALK inhibitors.
Team ALKItects @PatelOncology
#Fellowsforum @benlevylungdoc @Jani_Chinmay
Sarah Waliany, MD, MS retweeted
Closing US Focus Meeting on Lung Cancer in Nashville with panels on fusions and rare tumors with experts like Drs. @christine_lovly @JessicaJLinMD @SWaliany @ShirishGadgeel @chulkimMD @LudaBazhenovaMD @MMarmarelis - thanks to all who helped make the meeting such a success!
Sarah Waliany, MD, MS retweeted
With multiple MTA-cooperative #PRMT5i now in phase 1/2 trials, MTAP testing should be considered in oncogene-driven #NSCLC.
More than 1 in 3 patients with ALK+ disease may harbor MTAP loss.
Next step: TKI + PRMT5i combination trials.
@DanaFarber @GustaveRoussy @AlkRos1France @ALKPositiveinc
🆕 Article in press: MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies. @mihaela_aldea
👉 annalsofoncology.org/article…
Sarah Waliany, MD, MS retweeted
Please (re)watch the powerful Special Speech delivered by Dr. Ross Camidge @DRCamidge at #TTLC26 @IASLC
An internationally renowned thoracic oncologist, Dr. Camidge shared something profoundly personal: his own diagnosis and treatment journey with stage IV #EGFR-mutant #NSCLC. His reflections were thoughtful and deeply human.
It is a reminder that before we are physicians or patients, we are human beings: vulnerable yet resilient. Please:
❤️ Act with urgency.
❤️ Treat with respect and gentleness.
❤️ Move forward with courage and hope.
@ShirishGadgeel @lungoncdoc @KarenReckampMD @TejasPatilMD
At #TTLC26, @DRCamidge shared powerful insights shaped by both clinical expertise and personal experience living with #lungcancer.
His presentation reminds us why continued innovation in #lungcancer research is essential to improving patient outcomes every day.
bit.ly/46YrbUc
Sarah Waliany, MD, MS retweeted
A new first line standard of care for HER2 mutant NSCLC? Zongertinib receives accelerated approval as initial therapy based on Beamion LUNG-1 trial with 1L RR 76%. Part of the new FDA voucher program, approval granted 44 days after filing!
fda.gov/news-events/press-an…
Sarah Waliany, MD, MS retweeted
Update for RET NSCLC @CCR_AACR describes acquired resistance to selective RET inhibitors. The "RETgistry" included 109 pts with post-SRI biopsies and showed 14% with secondary RET mutations. Off target included MET (18%), KRAS (7%), CDKN2A/B (5%).
aacrjournals.org/clincancerr…
Sarah Waliany, MD, MS retweeted
Great insights from @JuliaRotow at #MaTOS on managing #ALK+ #NSCLC w/ lorlatinib beyond PD+LAT vs systemic therapy.
Timely, with new data from @SWaliany and our group showing the safety and activity of adding chemotherapy to next-gen ALK TKIs.@OncoAlert
doi.org/10.6004/jnccn.2025.7…
Sarah Waliany, MD, MS retweeted
Continuing ALK TKIs when starting chemotherapy for disease progression improves outcomes for patients with advanced ALK+ NSCLC. Thank you @SWaliany and @JessicaJLinMD for spearheading the effort and including us in this important work!
jnccn.org/view/journals/jncc…
Sarah Waliany, MD, MS retweeted
Fun reunion with two of my all-time best recruits to @StanfordMedRes & emerging super⭐️ physician-scientists @HanZhuMD & @SWaliany. The original team who launched the ICI-myocarditis troponin screening program @StanfordMed & @StanfordCancer! #AHA25 #CardioOnc
Sarah Waliany, MD, MS retweeted
It was an honor to present, on behalf of the co-investigators, the planned OS results from FLAURA2 ph III at #WCLC25. These results confirm a shift in our first-line practice for our EGFRm pts, marking the first time a study has achieved a significant benefit mOS of 4Y. #EGFR
Sarah Waliany, MD, MS retweeted
Dr. Jonathan Goldman presents the HARMONi data at #WCLC25. In EGFR NSCLC post TKI, adding ivonescimab (VEGF/PD1 bispecific) improves PFS (4.4 to 6.8m, HR 0.52). Numeric difference in OS in Western pts, but complicated analysis in heterogenous group. Improvement over MARIPOSA2?
